Joint Ventures: EULAR 2026 Congress Preview

About this episode

Hosts preview the upcoming EULAR 2026 Congress, discussing key sessions and themes in rheumatology.

In this episode of Joint Ventures , hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including: Obesity, Weight Management, and Psoriatic Arthritis Sessions Personalized Medicine and Biomarkers in RMDs Sessions Fatigue and Quality of Life in Connective Tissue Disease Session Mitochondrial DNA and Interferon: Upstream Drivers of Autoimmunity Session Artificial Intelligence and Pattern Recognition in Rheumatology Sessions Axial Imaging in Axial Spondyloarthritis Session Head-to-Head Superiority Trials in RA and PsA Sessions CAR-T and CAR-NK Therapies: Efficacy, Limits, and What Comes Next Sessions

People in this episode

Hosts: Jack Arnold, MBBS, PhD, Rihards Buss, MD

Topics covered

• Rheumatology
• EULAR Congress Preview
• Personalized Medicine
• Autoimmunity
• Artificial Intelligence in Medicine
• Quality of Life in Disease

Keywords

• EULAR 2026
• Rheumatology
• Psoriatic Arthritis
• Fatigue
• Quality of Life
• Artificial Intelligence
• Mitochondrial DNA

Mentioned in this episode

Places: London

More episodes of HCPLive Podcasts

• Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
• Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
• Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms · May 28, 2026 · 25 min
• Introducing Joint Ventures, With Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS · May 28, 2026 · 23 min